Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
作者信息
Gandhi Mitul D, Evens Andrew M, Fenske Timothy S, Hamlin Paul, Coiffier Bertrand, Engert Andreas, Moskowitz Alison J, Ghosh Nilanjan, Petrich Adam M, Lomasney Jon, Chadburn Amy, Wood Gary S, Salva Katrin, Nardone Beatrice, Trifilio Steven M, Raisch Dennis W, West Dennis P, Gordon Leo I, Winter Jane N
机构信息
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
出版信息
Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878.
Abstract
摘要
相似文献
1
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.接受本妥昔单抗治疗的患者发生胰腺炎：一种先前未被认识到的严重不良事件。
Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878.
2
Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.本妥昔单抗维迪昔单抗：一项在先前治疗失败的霍奇金淋巴瘤和系统性间变大细胞淋巴瘤患者中应用的综述。
Drugs. 2013 Mar;73(4):371-81. doi: 10.1007/s40265-013-0031-5.
3
Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.本妥昔单抗治疗多次复发的霍奇金淋巴瘤和间变性大细胞淋巴瘤：一项纳入45例患者的单中心研究
Br J Haematol. 2014 Jul;166(2):306-8. doi: 10.1111/bjh.12849. Epub 2014 Mar 27.
4
Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.在日本复发/难治性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤患者中，贝林妥欧单抗的安全性概况：一项上市后监测研究。
Int J Hematol. 2021 Mar;113(3):404-412. doi: 10.1007/s12185-020-03039-w. Epub 2021 Jan 3.
5
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
6
Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.本妥昔单抗：其在间变性大细胞淋巴瘤和霍奇金淋巴瘤治疗中的作用。
Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435.
7
Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.本妥昔单抗致淋巴瘤患者胰腺炎：一项药物警戒研究。
Leuk Lymphoma. 2022 Jul;63(7):1768-1769. doi: 10.1080/10428194.2022.2045601. Epub 2022 Mar 6.
8
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.意大利关于 brentuximab vedotin 的真实世界经验：40 例复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究结果。
Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.
9
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.本妥昔单抗维达汀不会导致 CD30 阳性血液恶性肿瘤患者出现临床相关的 QTc 间期延长。
Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.
10
Brentuximab vedotin.本妥昔单抗维迪西妥单抗。
Drugs R D. 2011;11(1):85-95. doi: 10.2165/11591070-000000000-00000.
引用本文的文献
1
Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer.癌症中靶向生长因子信号传导和免疫细胞的单克隆抗体相关毒性机制的最新进展。
Toxicol Res. 2024 Apr 22;40(3):335-348. doi: 10.1007/s43188-024-00233-4. eCollection 2024 Jul.
2
Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.用于难治性弥漫性皮肤系统性硬化症皮肤受累的本妥昔单抗，一项开放标签试验。
Rheumatology (Oxford). 2025 Mar 1;64(3):1476-1481. doi: 10.1093/rheumatology/keae235.
3
Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.贝林妥欧单抗的心脏毒性：FDA 不良事件报告系统（FAERS）数据库的真实世界比例失调分析。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):5253-5264. doi: 10.1007/s00210-024-02955-6. Epub 2024 Jan 25.
4
Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.复发或难治性间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤患儿的治疗策略：综述
Cancers (Basel). 2023 Dec 7;15(24):5733. doi: 10.3390/cancers15245733.
5
CAR-T Cell Therapy for Classical Hodgkin Lymphoma.嵌合抗原受体T细胞疗法治疗经典型霍奇金淋巴瘤
Hemasphere. 2023 Nov 16;7(12):e971. doi: 10.1097/HS9.0000000000000971. eCollection 2023 Dec.
6
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.用于淋巴瘤患者的抗体药物偶联物：临床前和临床证据
Explor Target Antitumor Ther. 2022;3(6):763-794. doi: 10.37349/etat.2022.00112. Epub 2022 Dec 26.
7
Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review.病例报告：儿童霍奇金淋巴瘤患者接受 Brentuximab Vedotin 治疗后发生急性胰腺炎：病例报告及文献复习。
Pathol Oncol Res. 2022 Aug 12;28:1610445. doi: 10.3389/pore.2022.1610445. eCollection 2022.
8
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.第三代抗 CD30 CAR T 细胞特异性归巢至肿瘤部位并发挥强大的抗肿瘤活性。
Sci Rep. 2022 Jun 21;12(1):10488. doi: 10.1038/s41598-022-14523-0.
9
Brentuximab vedotin induced uveitis.本妥昔单抗诱发了葡萄膜炎。
Am J Ophthalmol Case Rep. 2022 Feb 18;26:101440. doi: 10.1016/j.ajoc.2022.101440. eCollection 2022 Jun.
10
Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.贝林妥欧单抗联合替西利珠单抗治疗经典型霍奇金淋巴瘤患者发生肿瘤 flares 反应：1 例报告
Front Immunol. 2022 Jan 14;12:756583. doi: 10.3389/fimmu.2021.756583. eCollection 2021.
本文引用的文献
1
Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report.用于难治性霍奇金淋巴瘤的本妥昔单抗治疗后发生急性胰腺炎：一例报告
Drugs R D. 2014 Mar;14(1):9-11. doi: 10.1007/s40268-014-0036-x.
2
Genetic risk factors for pancreatic disorders.胰腺疾病的遗传风险因素。
Gastroenterology. 2013 Jun;144(6):1292-302. doi: 10.1053/j.gastro.2013.01.069.
3
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.美国食品和药物管理局批准概要：本妥昔单抗维泊妥珠单抗用于治疗复发的霍奇金淋巴瘤或复发的系统性间变性大细胞淋巴瘤。
Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.
4
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔（SGN-35）治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.
5
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
6
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.本妥昔单抗维迪昔（SGN-35）治疗复发性 CD30 阳性淋巴瘤。
N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.
7
Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II.免疫组织化学的定量分析——关于方法、实用性及半定量评估的问题II
Histopathology. 2006 Oct;49(4):411-24. doi: 10.1111/j.1365-2559.2006.02513.x.
Zotero 插件